Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
Dietary Approach to Improving QoL in ALS
We have had reports of an individual who utilized a modified Paleolithic diet and vitamin/ supplement program as part of his approach to managing ALS related symptoms. This individual has experienced stability in his ALS functional rating score and stable to improving strength over an 18 month period. There are also anecdotal reports of ALS patients who have utilized a dietary approach based on a Paleolithic eating plan of improved function. This is a safety study. We will be assessing if patients can implement the proposed modified Paleolithic diet (Wahls Elimination), if lean muscle mass is maintained on the study diet, and what changes occur in the ALS functional symptoms and quality of life.
Study visits: 3 total over 12 weeks. Screening prior to enrollment will include consent to
complete three 24-hour dietary recalls prior to the first study visit.
Visit 0. Subject will be seen in the University of Iowa Hospitals and Clinics (UIHC)
Neurology Clinic, prevention intervention center or clinical research unit to review the
consent, answer questions and sign the consent.
Subjects will provide phone numbers and best times for the dietitian to call for the dietary
recall interviews and will be given a 2-dimensional food portion booklet to assist with
reporting amount of food eaten.
Letters and a copy of the study consent will be sent to eligible ALS patients from the UIHC
ALS clinic with follow up calls as previously descried.
Questions will be answered, the consent will be reviewed. If the patient wants to participate
in the study, a Visit 1 will be scheduled and permission to complete the 24 hour dietary
recalls will be obtained.
Height and weight will be documented from the participant clinic visits (neurology and
primary care if needed) to obtain at least 2 weights and a height obtained in a clinic
setting in the prior 6 months to calculate a slope of projected weight loss per month and a
projected weight loss and muscle mass loss that may be observed at visit 2.
Visit 1. Subjects will be asked to fast for 12 hours prior to visit. Urine specific gravity
will be obtained. The target is 1.004 to 1.028. If the urine is too dilute, the patient is to
stop drinking and the other tests will be obtained and urine specific gravity will be
repeated. The urine specific gravity that is noted that is within the range -- will be the
target specific gravity for future BIS tests (ideally within .005). Patients are asked to
report with the same level of hydration for future tests. Resting energy expenditure, forced
vitality capacity and hand grip test will be completed. Fasting blood specimens and vital
signs will be obtained. Subjects will be provided with a snack (or asked to bring a snack).
Questionnaires will be completed. Subjects will be educated how the subject's personal family
history (genetic vulnerability) may have interacted with the patient's unique DNA and
lifetime of diet, lifestyle choices and environmental exposures to contributed to the
participants' current health circumstances. The subject will be instructed on a
stress-reducing practice on mindfulness and the subject will do a practice session of
mindfulness. The participant will be taught the study diet by the intervention dietitian. A
diet checklist that offers guidance to the subject in the form of prompts to eat the foods
that are recommended and to avoid those that are not recommended will be provided. The
subject and their adult companion will be given a study-compliant meal and will practice
recording the meal in the diet checklist to facilitate the learning of the principles of the
study diet and how to use the daily diet checklist. The subject and adult companion will be
instructed on mindful eating.
The study visit will take approximately 5 to 6 hours. The subject will be given a 'loaner'
food blending machine to use to make smoothies and soups that are compliant with the study
diet. The subject will be asked to add 20 grams of bone broth protein powder and consume that
in a study compliant smoothie or warm beverage each day to increase protein intake in a food
or beverage item that does not require chewing (such as a smoothie or soup.
After the study visit:
Subjects will work by telephone with the study dietitian as they implement the study diet and
stress reducing practice. The subject will be called 2 to 3 days after the visit by the study
dietitian to review the study diet and answer questions. The dietitian will call again in one
week to review the study diet with the study subject and ask how the participant is managing
the diet. The dietitian will ask the participant if they are willing to continue on the study
diet for the remainder of the study which is called the intervention phase of the study. If
he participant is willing to continue the study diet, they will begin adding the various
vitamins and supplements according to schedule in the diet checklist. If the participant does
not wish to continue the study diet, the coaching calls will stop. Even if the participant
resumes their usual diet, the participant will still come in for the end of study visit 3 at
12 weeks. The participant will not come back for 12 week visit.
Visit 2: 6 weeks.
Subjects will be asked to fast for 12 hours prior to visit. The patient will be weighed.
Urine specific gravity will be obtained. The target urine specific gravity for the patient
future BIS tests (ideally within .005) from the first BIS will be identified. A urine sample
will be obtained The urine specific gravity will be obtained and compared to the target
value. If the urine is too dilute, the patient is to stop drinking and the other tests will
be obtained and urine specific gravity will be repeated in 1 hour.
The changes in muscle mass between visit 1 and visit 2 will be calculated and compared to the
projected muscle mass loss. If the participant has lost more muscle mass than was projected,
the study dietitian will instruct the participant on strategies to increase calories and
protein while following the study diet. In addition, the participant will be asked to
increase the intake of bone broth protein to 40 grams per day.
This visit will take 3 hours.
Visit 3: End of Study visit at 12 weeks. Participants will return the blending machine. The
target urine specific gravity for the patient future BIS tests (ideally within .005) from the
first BIS will be identified. A urine sample will be obtained The urine specific gravity will
be obtained and compared to the target value. If the urine is too dilute, the patient is to
stop drinking and the other tests will be obtained and urine specific gravity will be
repeated in 1 hour. Patients are asked to report with the same level of hydration for future
tests.
Resting energy expenditure, forced vitality capacity and BIS will be completed. Fasting blood
specimens and vital signs will be obtained. Subjects will be able to eat a snack. The hand
grip test will be completed. Questionnaires will be completed. The study team will answer
questions about the study. Three 24 hour recalls will be completed in the week before and or
the week after the end of study visit.
The changes in muscle mass between visit 1 and visit 2 will be calculated and compared to the
projected muscle mass loss. The participant will be informed if the muscle mass is greater
than projected and will be informed of strategies to increase calorie and protein intake.
The study visit will take approximately 2 to 3 hours.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |